Commercial Services · Miscellaneous Commercial Services · NSE: CONCORDBIO · data 2026-10-09
Concord Biotech Ltd.
Health check: Average (4.5/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,361.4
Market cap
₹13,913 cr
P/E
51.7
P/B
—
ROE
13.6%
ROCE
15.1%
Debt / equity
0
Dividend yield
0.57%
1-year return
-15.1%
52-week high
₹1,621.5
52-week low
₹987
Operating margin
28.3%
Growth
| Revenue (last 12 months) | ₹1,108 cr |
| Net profit (last 12 months) | ₹275 cr |
| Sales growth, 3 years (yearly) | 8.0% |
| Profit growth, 3 years (yearly) | 2.8% |
Chart patterns
- Double top — breakdown (key level ₹1,411.6)
Similar companies
eClerx Services Limited (ECLERX) · Choice International Limited (CHOICEIN) · Central Mine Planning & Design Institute Limited (CMPDI) · Syngene International Ltd. (SYNGENE) · International Gemological Institute Ltd (IGIL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CONCORDBIO in NSE Scanner →